Spyre Therapeutics (SYRE) – Investment Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Spyre Therapeutics (NASDAQ: SYRE):

• 8/11/2026 – Spyre Therapeutics had its price target raised by BTIG Research from $112.00 to $132.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Spyre Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/5/2026 – Spyre Therapeutics was given a new $120.00 price target by Robert W. Baird.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Wells Fargo & Company from $90.00 to $115.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Wedbush from $100.00 to $130.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Spyre Therapeutics had its price target raised by Guggenheim from $115.00 to $130.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Spyre Therapeutics was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 7/13/2026 – Spyre Therapeutics had its price target raised by Mizuho from $84.00 to $120.00. They now have an “outperform” rating on the stock.
• 6/23/2026 – Spyre Therapeutics had its price target raised by Deutsche Bank Aktiengesellschaft from $115.00 to $135.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Spyre Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $100.00 price target on the stock.
• 6/15/2026 – Spyre Therapeutics had its price target raised by BTIG Research from $98.00 to $112.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $95.51, for a total value of $1,432,650.00. Following the completion of the sale, the chief executive officer directly owned 567,540 shares of the company’s stock, valued at $54,205,745.40. The trade was a 2.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sheldon Sloan sold 8,334 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $87.70, for a total transaction of $730,891.80. Following the transaction, the insider directly owned 8,334 shares in the company, valued at $730,891.80. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 142,167 shares of company stock valued at $12,779,292 in the last 90 days. Corporate insiders own 15.69% of the company’s stock.

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.